This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioProcess International
Delivered as a Hybrid Event Event
September 27-30, 2022Boston Convention and Exhibition Center

Katalin Karikó, PhD
Senior Vice President RNA Protein Replacement Therapy at BioNTech


Katalin Karikó works at BioNTech from 2013. Prior to that, she worked at the University of Pennsylvania for 24 years. She received her PhD in biochemistry from University of Szeged, Hungary, in 1982. Her thesis work involved synthesis and antiviral evaluation of short 2’-5’-linked oligonucleotides. For decades, her research has been focusing on RNA-mediated mechanisms with the ultimate goal of developing in vitro-transcribed mRNA for protein therapy. She investigated RNA-mediated immune activation and co-discovered that nucleoside modifications suppress immunogenicity of RNA. This groundbreaking work unlocked the opportunity for the therapeutic use of mRNA. Her patent, co-invented on nucleoside-modified uridines of mRNA, was the foundation for the FDA-approved COVID-19 mRNA vaccines developed by BioNTech/Pfizer and Moderna/NIH.

Agenda Sessions

  • BALLROOM WEST: Keynote Presentation: My Long Road from the 2’-5’ Oligos to the mRNA Vaccine